熱景生物(688068.SH):參股公司研製的創新藥SGC001注射液臨牀試驗申請獲批准許可
格隆匯8月5日丨熱景生物(688068.SH)公佈,參股公司北京舜景生物醫藥技術有限公司收到國家藥品監督管理局(NMPA)核准簽發的《藥物臨牀試驗批准通知書》,通知書編號2024LP01790,舜景醫藥研製的創新藥SGC001注射液臨牀試驗申請(IND)已獲得國家藥品監督管理局(NMPA)批准許可。SGC001是一款由舜景醫藥孫志偉教授研發團隊聯合首都醫科大學北京市心肺血管疾病研究所杜傑教授團隊共同開發研製的急救用單克隆抗體藥物,適用於急性心肌梗死(AcuteMyocardialInfarction,AMI)(首先開展的適應症為“前壁ST段抬高型心肌梗死”)患者的急救治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.